apollo

Select Address

Search Medicines
  • Login
  1. Home
  2. Revici-E 250 Tablet

  3. Revici-E 250 Tablet Substitute

Revici-E 250 Tablet Substitute

Substitutes safety advice
call Doctor

Verified Ingredients and Effects

Composition:

ETAMSYLATE-250MG

Uses:

Bleeding disorders (preventing and controlling bleeding from small blood vessels haemorrhage menorrhagia, neonatal intraventricular and periventricular haemorrhages).

Medicinal Benefits:

Revici-E 250 Tablet contains Etamsylate, a hemostatic agent that improves platelet adhesion by restoring capillary resistance and improving platelet adhesion. On the other hand, Revici-E 250 Tablet also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding. Thus it treats, controls, and improves various disease conditions and symptoms.

FAQs

Etamsylate, a hemostatic substance found in Revici-E 250 Tablet , works by restoring capillary resistance and enhancing platelet adhesion. On the other hand, Revici-E 250 Tablet also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding.

Yes, Revici-E 250 Tablet is contraindicated in people with known allergies to any of the components of this medicine. It should be avoided in people with porphyria (a group of rare inherited blood disorders).

In case you have missed a dose, skip the missed dose. Then resume your next dose as normal. Do not take a double dose in any case.

No, you are not recommended to stop using Revici-E 250 Tablet without consulting your doctor, as it may cause recurring bleeding. Therefore, take Revici-E 250 Tablet for as long as your doctor has prescribed it, and if you are experiencing any difficulty while taking Revici-E 250 Tablet , please consult your doctor.

Majority of cases, Revici-E 250 Tablet is prescribed by your doctor for prevention and control of bleeding from small blood vessels haemorrhage menorrhagia and neonatal intraventricular haemorrhage. Besides this, it can also be used to prevent periventricular haemorrhages in prematurely born children.